Invitrogen Corp. Unveils CloneMiner cDNA Library Construction Kit; New System Allows Unprecedented Access to Intact Clones for Researchers.Business Editors & Health/Medical Writers BIOWIRE2K CARLSBAD, Calif.--(BUSINESS WIRE)--Feb. 12, 2003 Invitrogen Corp. (Nasdaq:IVGN), a global leader in molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller and cell culture research products, today introduced the CloneMiner(TM) cDNA Library A cDNA library is a collection of clones containing cDNAs. cDNA libraries are often intended to represent as many as possible of the mRNAs contained within a cell. Because working with mRNA is difficult (as mRNA is unstable and is easily degraded by RNases which can be found even Construction Kit, offering researchers a fast method of building high-quality libraries in a recombination-based cloning cloning: see clone. To make a product that functions like another. See clone. See also cloning software. system. The CloneMiner(TM) technology does not require restriction enzymes restriction enzyme Protein (more specifically, an endonuclease) produced by bacteria that cleaves DNA at specific sites along its length. Thousands have been found, from many different bacteria; each recognizes a specific nucleotide sequence. in the cloning process, enabling scientists to obtain full-length clones never before accessible in traditional library construction methods. In addition, the system makes the process of building a high-quality library practical for researchers of all experience levels. "Researchers want access to previously undiscovered, fully-intact cDNA clones," said Matthew Klimjack, product manager for Invitrogen's Cloning and Gene Expression group. "Our new system allows them to `mine' for clones that they know exist, but would not have access to otherwise, while also saving time, energy and resources in library construction." The CloneMiner(TM) kit draws upon Invitrogen's SuperScript Any letter, digit or symbol that appears above the line. For example, 10 to the 9th power is written with the 9 in superscript (109). Contrast with subscript. (TM) II and Gateway(R) technologies, enabling high cDNA yields, as well as versatility and ease of transfer to expression systems. CloneMiner(TM) also eliminates the cutting of cDNA to make it compatible for directional In one direction. Contrast with omnidirectional. cloning, and avoids inefficient ligations of clones into expression vectors expression vector n. A vector, such as a plasmid, yeast, or animal virus genome, used to introduce foreign genetic material into a host cell in order to replicate and amplify the foreign DNA sequences as a recombinant molecule. . Invitrogen's CloneMiner(TM) kit provides greater access to high-quality cDNA and greater probability of obtaining full-length clones, as well as promoting easy, rapid transfer of single clones or entire libraries directly into an expression vector. About Invitrogen Invitrogen provides essential technologies to biotechnology and biopharmaceutical researchers and companies worldwide. Invitrogen manufactures and markets a breadth of products for life sciences discovery, development and production. These include research tools in kit form and catalog catalog, descriptive list, on cards or in a book, of the contents of a library. Assurbanipal's library at Nineveh was cataloged on shelves of slate. The first known subject catalog was compiled by Callimachus at the Alexandrian Library in the 3d cent. B.C. and custom products and service for corporate, academic and government entities. Invitrogen also engages in technology licensing, research service, large-scale production, and life science technical expertise and support. With operations in more than 20 countries and distributor relationships in 50 more, Invitrogen employs approximately 2500 people at its worldwide locations. For more information about Invitrogen visit the web site at www.invitrogen.com. Certain statements contained in this press release are considered "forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. " within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. created thereby. Such statements include, but are not limited to, statements relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc : 1) CloneMiner cDNA Library Construction Kit enabling researchers to build high-quality libraries in a recombination-based cloning system more quickly 2) CloneMiner cDNA Library Construction Kit enabling researchers to obtain clones never before accessible; 3) whether researchers at all levels of experience will find CloneMiner kits more practical than current library construction methods; 4) whether researchers will save time and resources in library construction using CloneMiner kits; 5) whether CloneMiner in conjunction with Gateway and SuperScript II technologies will enable high cDNA yields or ease transfer to expression systems; and 6) whether CloneMiner, Gateway and SuperScript II products will provide greater access to high-quality cDNA and greater probability of obtaining full-length clones. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to: a) competitive technologies, products or changes in scientific research or funding; b) the specific cDNA library construction methods or conditions a researcher may be using; c) the method or type cDNA library construction technology a researcher is currently using or has used; d) the way in which a researcher incorporates the CloneMiner cDNA Library Construction Kit into their own cloning or gene expression experiments or assays; and e) the extent to which the research community adopts the use of the CloneMiner cDNA Library Construction Kit; as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion